PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.
Vancouver, British Columbia--(Newsfile Corp. - March 25, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has obtained a default judgement against each of Essos Corporate Services Inc. ("Essos") and Detona Capital Corp. ("Detona") in connection with a Supreme Court of British Columbia action (the "Action"). The Action was brought by PreveCeutical in December 2018, against a group of defendants (the "Defendants") for...
2019-03-25 8:00 AM EDT
PreveCeutical Announces Preliminary Screening Results of Peptides Derived From Blue Scorpion Venom in a Cell-Based Brain Cancer Model
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program (the "Peptide Program"), that is expected to enable the Company to generate Nature Identical™ peptide therapeutics intended for therapeutic applications. PreveCeutical's...
2019-03-11 9:00 AM EDT
PreveCeutical Announces Appointment of Dr. Makarand Jawadekar as President
Vancouver, British Columbia--(Newsfile Corp. - February 13, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce the appointment of Dr. Makarand (Mak) Jawadekar as the President of the Company, effective immediately. Dr. Jawadekar will also continue as the Chief Science Officer and as a director of the Company. Former President, Mr. Stephen Van Deventer, will continue to serve as Chairman and CEO of PreveCeutical....
2019-02-13 8:30 AM EST
PreveCeutical Announces Closing of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - February 12, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces the closing of a non-brokered private placement financing (the "Financing"). A total of 6,100,000 units (the "Units") were issued under the Financing at a price of $0.05 per Unit for gross proceeds of $305,000. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one common share...
2019-02-12 8:30 AM EST
PreveCeutical to Explore Partnerships with Pharmaceutical and Biotechnology Companies for the Co-Development of its Sol-Gel System
Vancouver, British Columbia--(Newsfile Corp. - January 29, 2019) - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), announces that it plans to commence exploratory discussions with pharmaceutical and biotechnology companies developing therapies for neurological disorders, that are seeking a targeted nose-to-brain drug delivery system in connection with same, with the intention of forming a partnership for the co-development of the Company's...
2019-01-29 8:00 AM EST
PreveCeutical Provides Update on the Dual Gene Therapy Program
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to provide an update on its dual gene therapy program, an important and fundamental aspect of which involves the design, synthesis and screening of small interfering RNA (siRNA) constructs in downregulating the Company's target gene of interest, in type 2 diabetes and obesity. The design process involves strategic...
2019-01-14 8:30 AM EST
PreveCeutical Provides Update on Research Program for Development of Non-Addictive Analgesics
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce that it has recently completed a systematic and comprehensive series of in silico guided design, synthesis and potency screening of a library of carefully designed peptide constructs intended for development as non-addictive analgesics. Through this meticulous process we have identified no less than five...
2019-01-08 8:30 AM EST
PreveCeutical Files Notice of Civil Claim Against the BridgeMark Group
Vancouver, British Columbia--(Newsfile Corp. - January 7, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that on December 17, 2018 it filed a Notice of Civil Claim with the Supreme Court of British Columbia (the "Notice of Civil Claim") against Aly Babu Mawji, Justin Liu, BridgeMark Financial Corp., Rockshore Advisors Ltd. (formerly known as, Cam Paddock Enterprises Inc.), Detona Capital Corp., Escher Invest SA, Essos...
2019-01-07 9:00 AM EST
PreveCeutical Provides Year End Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to provide an update on the Company's progress in its ongoing corporate initiatives. PreveCeutical has achieved several notable milestones this year and continues to execute its strategy to become a global preventive healthcare company. These milestones include: signing a letter of intent with Crushedit LLC...
2018-12-19 9:30 AM EST
PreveCeutical Responds to British Columbia Securities Commission Press Release
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") acknowledges that it was mentioned in a press release disseminated by the British Columbia Securities Commission (the "BCSC") on November 26, 2018 concerning certain allegations made by the BCSC against a group of individuals and corporate entities, including certain individuals and corporate entities that were previously...
2018-11-28 9:30 AM EST
PreveCeutical Converts Acidic Phytocannabinoids to Neutral Form and Doubles Contents of Fingerprinted Cannabis Extract Library
Vancouver, British Columbia--(Newsfile Corp. - November 20, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has developed an optimized protocol to convert phytocannabinoids extracted from the Company's five cannabis strains from their acid forms to their neutral forms (the "Neutralization Protocol"). Specifically, the Company's Neutralization Protocol has confirmed the comprehensive conversion of cannabidiolic acid...
2018-11-20 9:00 AM EST
PreveCeutical Confirms Encouraging Results from Sol-gel Applicator Trials for Achieving Direct Nose-to-Brain Delivery in an Adult Human Nasal Cast
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update on the soluble gel ("Sol-gel") drug delivery research and development program (the "Sol-gel Program"), that involves testing and formulating an array of cannabis strains for the development and commercialisation of cannabinoid-based Sol-gels. The Sol-gels are administered using a custom...
2018-11-19 7:00 AM EST
PreveCeutical Announces LOI with Crushedit LLC to Supply CBD Isolate for Expected Sale Proceeds of $16.25 Million
Vancouver, British Columbia--(Newsfile Corp. - November 13, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), (the "Company" or "PreveCeutical") announces that it has entered into a non-binding letter of intent dated November 9, 2018 (the "LOI") with Crushedit LLC ("Crushedit"), whereby PreveCeutical's newly created Cannabis Division (see news release dated July 24, 2018) will supply Crushedit with a minimum of 2,500 kilograms of Cannabidiol ("CBD") isolate over a 12...
2018-11-13 9:00 AM EST
PreveCeutical Applies its Proprietary Extraction Protocol for Medical Cannabinoids to Two Additional Cannabis Strains
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, in connection with its soluble gel drug delivery research and development program (the "Sol-gel Program"), it has now optimised the conditions for extracting cannabinoids from two additional cannabis strains provided by the Company's licensed producer (LP) partner, Aurora Cannabis Inc. ("Aurora"). The two...
2018-11-05 9:00 AM EST
PreveCeutical Provides Update on Visit to Penta 5 Group's Facility for Due Diligence on Proposed Acquisition
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), provides an update on its recent due diligence trip (the "Due Diligence Trip") to view a facility operated by the Penta 5 group of companies (the "Penta 5 Group") in connection with the Company's proposed acquisition (the "Acquisition") of the Penta 5 Group and its assets (see news release dated October 3, 2018). The Due...
2018-10-31 9:00 AM EDT
PreveCeutical Holds Intensive Workshop to Advance Dual Gene Therapy Research Program for Type 2 Diabetes and Obesity
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that its research team at the University of Queensland, recently held a two-day intensive workshop (the "Workshop"), which brought together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth (the "Teams") to collaborate on...
2018-10-30 9:00 AM EDT
PreveCeutical to Visit Penta 5 Group's Packaging Facility for Due Diligence on Proposed Acquisition
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces an update on the Company's due diligence on the Penta 5 group of companies (the "Penta 5 Group"), in connection with the proposed acquisition by the Company of the Penta 5 Group (the "Acquisition") and its assets, which include over seven brands, 40 market-ready products, previously announced on October 3, 2018. To...
2018-10-15 6:30 AM EDT
PreveCeutical Announces LOI to Acquire Penta 5 Health and Wellness Packaging Companies with Market-Ready Products and Production Facilities
Vancouver, British Columbia--(Newsfile Corp. - October 3, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that the Company has entered into a letter of intent dated October 1, 2018 (the "LOI") with Penta 5 Packaging Inc. ("Penta 5 Canada") and Penta 5 USA, LLC ("Penta 5 USA" together with Penta 5 Canada and their subsidiaries, the "Penta 5 Group"), both of which are arm's length parties to the Company, with respect to a...
2018-10-03 3:57 PM EDT
PreveCeutical Engages Invictus Resources to Provide Investor Awareness Services
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into a Master Services Agreement dated effective October 1, 2018 (the "Agreement") with World Wide Holdings LLC, DBA Invictus Resources ("Invictus"), whereby Invictus will provide investor awareness services (the "Services") to the Company involving the selection and coordination of investor...
2018-09-28 7:25 PM EDT
PreveCeutical Enters into Development Agreement with Asterion Cannabis Inc. to Develop Medicinal Cannabinoid Products
Vancouver, British Columbia--(Newsfile Corp. - September 26, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), and Asterion Cannabis Inc. ("Asterion") announce that they have entered into a development and joint venture agreement (the "Development Agreement") to form a joint venture ("Joint Venture") to develop a range of medicinal cannabinoid products, including sublingual tablets, transdermal patches, and other jointly evaluated products aimed at...
2018-09-26 6:30 AM EDT